Loading...
Repression of BET activity sensitizes homologous recombination–proficient cancers to PARP inhibition
Strategies to enhance response to poly(adenosine diphosphate–ribose) polymerase inhibitor (PARPi) in primary and acquired homologous recombination (HR)–proficient tumors would be a major advance in cancer care. We used a drug synergy screen that combined a PARPi, olaparib, with 20 well-characterized...
Saved in:
| Published in: | Sci Transl Med |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2017
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5705017/ https://ncbi.nlm.nih.gov/pubmed/28747513 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.aal1645 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|